Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer.

Cancer cell | 2018

Driver mutations in oncogenes encode proteins with gain-of-function properties that enhance fitness. Heterozygous mutations are thus viewed as sufficient for tumorigenesis. We describe widespread oncogenic mutant allele imbalance in 13,448 prospectively characterized cancers. Imbalance was selected for through modest dosage increases of gain-of-fitness mutations. Negative selection targeted haplo-essential effectors of the spliceosome. Loss of the normal allele comprised a distinct class of imbalance driven by competitive fitness, which correlated with enhanced response to targeted therapies. In many cancers, an antecedent oncogenic mutation drove evolutionarily dependent allele-specific imbalance. In other instances, oncogenic mutations co-opted independent copy-number changes via the evolutionary process of exaptation. Oncogenic allele imbalance is a pervasive evolutionary innovation that enhances fitness and modulates sensitivity to targeted therapy.

Pubmed ID: 30393068 RIS Download

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: R25 CA020449
  • Agency: NCI NIH HHS, United States
    Id: R37 CA072614
  • Agency: NCI NIH HHS, United States
    Id: R01 CA204749
  • Agency: NCI NIH HHS, United States
    Id: R01 CA207244
  • Agency: NIH HHS, United States
    Id: U54 OD020355
  • Agency: NIGMS NIH HHS, United States
    Id: T32 GM007175
  • Agency: NCI NIH HHS, United States
    Id: P30 CA008748
  • Agency: NCI NIH HHS, United States
    Id: T32 CA009207
  • Agency: NCI NIH HHS, United States
    Id: P50 CA092629
  • Agency: NCI NIH HHS, United States
    Id: R01 CA204999
  • Agency: NCI NIH HHS, United States
    Id: R01 CA180037

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Addgene (tool)

RRID:SCR_002037

Non-profit plasmid repository dedicated to helping scientists around the world share high-quality plasmids. Facilitates archiving and distributing DNA-based research reagents and associated data to scientists worldwide. Repository contains over 65,000 plasmids, including special collections on CRISPR, fluorescent proteins, and ready-to-use viral preparations. There is no cost for scientists to deposit plasmids, which saves time and money associated with shipping plasmids themselves. All plasmids are fully sequenced for validation and sequencing data is openly available. We handle the appropriate Material Transfer Agreements (MTA) with institutions, facilitating open exchange and offering intellectual property and liability protection for depositing scientists. Furthermore, we curate free educational resources for the scientific community including a blog, eBooks, video protocols, and detailed molecular biology resources.

View all literature mentions

cBioPortal (tool)

RRID:SCR_014555

A portal that provides visualization, analysis and download of large-scale cancer genomics data sets.

View all literature mentions

OncoKB (tool)

RRID:SCR_014782

Precision oncology knowledge base which contains information about the effects and treatment implications of specific cancer gene alterations. OncoKB contains detailed information about specific alterations in 418 cancer genes. Each variant entry contains biological effect, prevalence, prognostic information, and treatment implications. Information is curated from various sources, such as guidelines from the FDA, ClinicalTrials.gov, and scientific literature by a network of clinical fellows, research fellows, and faculty members at Memorial Sloan Kettering Cancer Center.

View all literature mentions

p44/42 MAPK (Erk1/2) Antibody (antibody)

RRID:AB_330744

This polyclonal targets p44/42 MAPK (Erk1/2)

View all literature mentions

MEK1/2 Antibody (antibody)

RRID:AB_823567

This polyclonal targets MEK1/2

View all literature mentions

Phospho-MEK1/2 (Ser217/221) Antibody (antibody)

RRID:AB_331648

This polyclonal targets Phospho-MEK1/2 (Ser217/221)

View all literature mentions

SK-BR-3 (cell line)

RRID:CVCL_0033

Cell line SK-BR-3 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

HEK293 (cell line)

RRID:CVCL_0045

Cell line HEK293 is a Transformed cell line with a species of origin Homo sapiens (Human)

View all literature mentions

R Project for Statistical Computing (software resource)

RRID:SCR_001905

Software environment and programming language for statistical computing and graphics. R is integrated suite of software facilities for data manipulation, calculation and graphical display. Can be extended via packages. Some packages are supplied with the R distribution and more are available through CRAN family.It compiles and runs on wide variety of UNIX platforms, Windows and MacOS.

View all literature mentions

R Project for Statistical Computing (software resource)

RRID:SCR_001905

Software environment and programming language for statistical computing and graphics. R is integrated suite of software facilities for data manipulation, calculation and graphical display. Can be extended via packages. Some packages are supplied with the R distribution and more are available through CRAN family.It compiles and runs on wide variety of UNIX platforms, Windows and MacOS.

View all literature mentions

HEK293 (cell line)

RRID:CVCL_0045

Cell line HEK293 is a Transformed cell line with a species of origin Homo sapiens (Human)

View all literature mentions

SK-BR-3 (cell line)

RRID:CVCL_0033

Cell line SK-BR-3 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

p44/42 MAPK (Erk1/2) Antibody (antibody)

RRID:AB_330744

This polyclonal targets p44/42 MAPK (Erk1/2)

View all literature mentions

MEK1/2 Antibody (antibody)

RRID:AB_823567

This polyclonal targets MEK1/2

View all literature mentions

Phospho-MEK1/2 (Ser217/221) Antibody (antibody)

RRID:AB_331648

This polyclonal targets Phospho-MEK1/2 (Ser217/221)

View all literature mentions